Results 31 to 40 of about 157,671 (305)

Kontroversi Fatwa Astrazeneca: Kontestasi Atau Harmonisasi?

, 2023
: The fatwas difference occurred between the Central MUI and the regionsover the legal assessment of the AstraZeneca Vaccine containing pork trypsin in the manufacturing process; this later became a discussion on the halal status and sanctity of the ...
Perdana Putra Pangestu, Shofiyullah Muzammil   +1 more
core   +2 more sources

Convenio de colaboración entre Barcelona Activa y Astrazeneca

, 2023
Aprovat entre Barcelona Activa i Astrazeneca el 11-01 ...
AstraZeneca (Firma), Barcelona Activa, S.A.U., S.P.M.   +1 more
core  

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

npj Breast Cancer, 2023
Combining the selective AKT inhibitor, capivasertib, and SERD, fulvestrant improved PFS in a Phase III clinical trial (CAPItello-291), treating HR+ breast cancer patients following aromatase inhibitors, with or without CDK4/6 inhibitors.
Lorna Hopcroft, Eleanor M. Wigmore, Stuart C. Williamson, Susana Ros, Cath Eberlein, Jennifer I. Moss, Jelena Urosevic, Larissa S. Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J. A. Goodwin, Brandon S. Willis, Claire Rooney, Elza C. de Bruin, Simon T. Barry   +20 more
doaj   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source

Evaluating the Side Effects of COVID-19 Vaccines Available in Al-Diwaniyah Province

Medical Journal of Babylon
Background:Vaccines are critical to reducing the viral attack by permitting the body to generate a safe immune response that defends it by preventing or limiting infection.
Meraim Attyah Kazaal, Roaa Abid Jaythoom, Noor Dakil Mahdi, Doaa Yousief Mohammed   +3 more
doaj   +1 more source

The communicated CSR structure of AstraZeneca and Pfizer - and some reflective suggestions [PDF]

, 2013
Several patents of description drugs are running out and numerous cheaper generics copies threatens to take place on the market. In order to ensure quality of the products and low burden on the society, regarding environmental and social aspects, the ...
Klaesson, Oskar, Arvidsson, Emelie
core  

Vacuna COVID-19 Oxford / AstraZeneca - Vaxzevria [fullet]

, 2021
Coronavirus SARS-CoV-2; COVID-19; 2019-nCov; Vacuna; Oxford/AstraZeneca; IndicacionsCoronavirus SARS-CoV-2; COVID-19; 2019-nCov; Vacuna; Oxford/AstraZeneca; IndicacionesCoronavirus SARS-CoV-2; COVID-19; 2019-nCov; Vaccine; Oxford/AstraZeneca ...

core  

Vacunació amb vacuna d’Oxford-AstraZeneca [PDF]

, 2021
Coronavirus SARS-CoV-2; COVID-19; 2019-nCov; Vacuna; Oxford/AstraZenecaCoronavirus SARS-CoV-2; COVID-19; 2019-nCov; Vacuna; Oxford/AstraZenecaCoronavirus SARS-CoV-2; COVID-19; 2019-nCov; Vaccine; Oxford/AstraZenecaPublicació adreçada a infermers sobre el
Cabezas-Peña, Carmen
core  

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Novel non-terminal tumor sampling procedure using fine needle aspiration supports immuno-oncology biomarker discovery in preclinical mouse models

Journal for ImmunoTherapy of Cancer, 2021
Background Immuno-oncology therapies are now part of the standard of care for cancer in many indications. However, durable objective responses remain limited to a subset of patients.
Robert W Wilkinson, Hormas Ghadially, Stacy Kentner, Suzanne Isabelle Sitnikova, Sophie Munnings-Tomes, Elena Galvani, Kathy Mulgrew, Chris Rands, Judit España Agustí, Tianhui Zhang, Kristina M Ilieva, Guglielmo Rosignoli, Matthew J Robinson, Tim Slidel, Simon J Dovedi   +14 more
doaj   +1 more source